Anti-hypertensives that modify the renin angiotensin system may reduce Alzheimer’s disease (AD) pathology and reduce the rate of disease progression.
Objective:
To conduct a phase II, two arm, double-blind, placebo-controlled, randomized trial of losartan to test the efficacy of Reducing pathology in Alzheimer’s Disease through Angiotensin TaRgeting (RADAR).
Methods:
Men and women aged at least 55 years with mild-to-moderate AD will be randomly allocated 100 mg encapsulated generic losartan or placebo once daily for 12 months after successful completion of a 2-week open-label phase and 2-week placebo washout to establish drug tolerability. 228 participants will provide at least 182 subjects with final assessments to provide 84% power to detect a 25% difference in atrophy rate (therapeutic benefit) change over 12 months at an alpha level of 0.05. We will use intention-to-treat analysis, estimating between-group differences in outcomes derived from appropriate (linear or logistic) multivariable regression models adjusting for minimization variables.
Results:
The primary outcome will be rate of whole brain atrophy as a surrogate measure of disease progression. Secondary outcomes will include changes to 1) white matter hyperintensity volume and cerebral blood flow; 2) performance on a standard series of assessments of memory, cognitive function, activities of daily living, and quality of life. Major assessments (for all outcomes) and relevant safety monitoring of blood pressure and bloods will be at baseline and 12 months. Additional cognitive assessment will also be conducted at 6 months along with safety blood pressure and blood monitoring. Monitoring of blood pressure, bloods, and self-reported side effects will occur during the open-label phase and during the majority of the post-randomization dispensing visits.
Conclusion:
This study will identify whether losartan is efficacious in the treatment of AD and whether definitive Phase III trials are warranted.
FerriCP, PrinceM, BrayneC, BrodatyH, FratiglioniL, GanguliM, HallK, HasegawaK, HendrieH, HuangY, JormA, MathersC, MenezesPR, RimmerE, ScazufcaM (2005) Global prevalence of dementia: A Delphi consensus study. Lancet366, 2112–2117.
2.
KehoePG, MinersS, LoveS (2009) Angiotensins in Alzheimer’s disease-friend or foe?Trends Neurosci32, 619–628.
3.
PiauA, NourhashemiF, HeinC, CaillaudC, VellasB (2011) Progress in the development of new drugs in Alzheimer’s disease. J Nutr Health Aging15, 45–57.
4.
Gillette GuyonnetS, Abellan Van KanG, AndrieuS, AquinoJP, ArbusC, BecqJP, BerrC, BismuthS, ChamontinB, DantoineT, DartiguesJF, DuboisB, FraysseB, HerguetaT, HanaireH, JeandelC, LagleyreS, LalaF, NourhashemiF, OussetPJ, PortetF, RitzP, RobertP, RollandY, SanzC, SotoM, TouchonJ, VellasB (2008) Prevention of progression to dementia in the elderly: Rationale and proposal for a health-promoting memory consultation (an IANA Task Force). J Nutr Health Aging12, 520–529.
5.
KivipeltoM, HelkalaEL, LaaksoMP, HanninenT, HallikainenM, AlhainenK, SoininenH, TuomilehtoJ, NissinenA (2001) Midlife vascular risk factors and Alzheimer’s disease in later life: Longitudinal, population based study. BMJ322, 1447–1451.
6.
LaunerLJ, RossGW, PetrovitchH, MasakiK, FoleyD, WhiteLR, HavlikRJ (2000) Midlife blood pressure and dementia: The Honolulu-Asia aging study. Neurobiol Aging21, 49–55.
7.
SkoogI, GustafsonD (2006) Update on hypertension and Alzheimer’s disease. Neurol Res28, 605–611.
8.
HonigLS, TangMX, AlbertS, CostaR, LuchsingerJ, ManlyJ, SternY, MayeuxR (2003) Stroke and the risk of Alzheimer disease. Arch Neurol60, 1707–1712.
9.
DaviesNM, KehoePG, Ben-ShlomoY, MartinRM (2011) Associations of anti-hypertensive treatments with Alzheimer’s disease, vascular dementia, and other dementias. J Alzheimers Dis26, 699–708.
10.
LiNC, LeeA, WhitmerRA, KivipeltoM, LawlerE, KazisLE, WolozinB (2010) Use of angiotensin receptor blockers and risk of dementia in a predominantly male population: Prospective cohort analysis. BMJ340, b5465.
CarmichaelO, SchwarzC, DruckerD, FletcherE, HarveyD, BeckettL, JackCRJr., WeinerM, DeCarliC (2010) Longitudinal changes in white matter disease and cognition in the first year of the Alzheimer disease neuroimaging initiative. Arch Neurol67, 1370–1378.
13.
HanonO, LatourF, SeuxML, LenoirH, ForetteF, RigaudAS (2005) Evolution of blood pressure in patients with Alzheimer’s disease: A one year survey of a French Cohort (REAL.FR). J Nutr Health Aging9, 106–111.
14.
HongKS, KangDW, BaeHJ, KimYK, HanMK, ParkJM, RhaJH, LeeYS, KooJS, ChoYJ, KwonSU, KimSE, ParkSH (2010) Effect of cilnidipine vs losartan on cerebral blood flow in hypertensive patients with a history of ischemic stroke: A randomized controlled trial. Acta Neurol Scand121, 51–57.
15.
NiwaK, YounkinL, EbelingC, TurnerSK, WestawayD, YounkinS, AsheKH, CarlsonGA, IadecolaC (2000) Abeta 1-40-related reduction in functional hyperemia in mouse neocortex during somatosensory activation. Proc Natl Acad Sci U S A97, 9735–9740.
16.
ZhaoZ, TuorUI, BarberP (2009) Chronic treatment with losartan and cerebral ischemic tolerance. J Exp Stroke Transl Med2, 9.
17.
BueeL, HofPR, BourasC, DelacourteA, PerlDP, MorrisonJH, FillitHM (1994) Pathological alterations of the cerebral microvasculature in Alzheimer’s disease and related dementing disorders. Acta Neuropathol87, 469–480.
18.
KalariaRN (2009) Linking cerebrovascular defense mechanisms in brain ageing and Alzheimer’s disease. Neurobiol Aging30, 1512–1514.
19.
LambertJC, DallongevilleJ, EllisKA, Schraen-MaschkeS, LuiJ, LawsS, DumontJ, RichardF, CottelD, BerrC, AmesD, MastersCL, RoweCC, SzoekeC, TzourioC, DartiguesJF, BueeL, MartinsR, AmouyelP (2011) Association of plasma ass peptides with blood pressure in the elderly. PLoS One6, e18536.
20.
van OijenM, HofmanA, SoaresHD, KoudstaalPJ, BretelerMM (2006) Plasma Abeta(1-40) and Abeta(1-42) and the risk of dementia: A prospective case-cohort study. Lancet Neurol5, 655–660.
21.
MinersJS, AshbyE, Van HelmondZ, ChalmersKA, PalmerLE, LoveS, KehoePG (2008) Angiotensin-converting enzyme (ACE) levels and activity in Alzheimer’s disease, and relationship of perivascular ACE-1 to cerebral amyloid angiopathy. Neuropathol Appl Neurobiol34, 181–193.
22.
MinersJS, BaigS, TaylerH, KehoePG, LoveS (2009) Neprilysin and insulin-degrading enzyme levels are increased in Alzheimer disease in relation to disease severity. J Neuropathol Exp Neurol68, 902–914.
23.
AkatsuH, OgawaN, KanesakaT, HoriA, YamamotoT, MatsukawaN, MichikawaM (2011) Higher activity of peripheral blood angiotensin-converting enzyme is associated with later-onset of Alzheimer’s disease. J Neurol Sci300, 67–73.
24.
LehmannDJ, Cortina-BorjaM, WardenDR, SmithAD, SleegersK, PrinceJA, van DuijnCM, KehoePG (2005) Large meta-analysis establishes the ACE insertion-deletion polymorphism as a marker of Alzheimer’s disease. Am J Epidemiol162, 305–317.
RogawskiMA, WenkGL (2003) The neuropharmacological basis for the use of memantine in the treatment of Alzheimer’s disease. CNS Drug Rev9, 275–308.
30.
CulmanJ, von HeyerC, PiepenburgB, RascherW, UngerT (1999) Effects of systemic treatment with irbesartan and losartan on central responses to angiotensin II in conscious, normotensive rats. Eur J Pharmacol367, 255–265.
31.
DeKoskyST, ShihWJ, SchmittFA, CoupalJ, KirkpatrickC (1990) Assessing utility of single photon emission computed tomography (SPECT) scan in Alzheimer disease: Correlation with cognitive severity. Alzheimer Dis Assoc Disord4, 14–23.
32.
ImranMB, KawashimaR, AwataS, SatoK, KinomuraS, OnoS, SatoM, FukudaH (1999) Tc-99m HMPAO SPECT in the evaluation of Alzheimer’s disease: Correlation between neuropsychiatric evaluation and CBF images. J Neurol Neurosurg Psychiatry66, 228–232.
33.
ShiraishiH, ChangCC, KannoH, YamamotoI (2004) The relationship between cerebral blood flow and cognitive function in patients with brain insult of various etiology. J Clin Neurosci11, 138–141.
34.
DanielyanL, KleinR, HansonLR, BuadzeM, SchwabM, GleiterCH, FreyWH (2010) Protective effects of intranasal losartan in the APP/PS1 transgenic mouse model of Alzheimer disease. Rejuvenation Res13, 195–201.
35.
FogariR, MugelliniA, ZoppiA, DerosaG, PasottiC, FogariE, PretiP (2003) Influence of losartan and atenolol on memory function in very elderly hypertensive patients. J Hum Hypertens17, 781–785.
36.
TedescoMA, RattiG, MennellaS, ManzoG, GriecoM, RainoneAC, IarussiD, IaconoA (1999) Comparison of losartan and hydrochlorothiazide on cognitive function and quality of life in hypertensive patients. Am J Hypertens12, 1130–1134.
37.
TedescoMA, RattiG, Di SalvoG, NataleF (2002) Does the angiotensin II receptor antagonist losartan improve cognitive function?Drugs Aging19, 723–732.
38.
McGuinnessB, ToddS, PassmoreAP, BullockR (2008) Systematic review: Blood pressure lowering in patients without prior cerebrovascular disease for prevention of cognitive impairment and dementia. J Neurol Neurosurg Psychiatry79, 4–5.
39.
AndersonC, TeoK, GaoP, ArimaH, DansA, UngerT, CommerfordP, DyalL, SchumacherH, PogueJ, PaolassoE, HolwerdaN, ChazovaI, BinbrekA, YoungJ, YusufS (2011) Renin-angiotensin system blockade and cognitive function in patients at high risk of cardiovascular disease: Analysis of data from the ONTARGET and TRANSCEND studies. Lancet Neurol10, 43–53.
40.
StaessenJA, ThijsL, RichartT, OdiliAN, BirkenhagerWH (2011) Placebo-controlled trials of blood pressure-lowering therapies for primary prevention of dementia. Hypertension57, e6–e7.
41.
HajjarI, HartM, MilbergW, NovakV, LipsitzL (2009) The rationale and design of the antihypertensives and vascular, endothelial, and cognitive function (AVEC) trial in elderly hypertensives with early cognitive impairment: Role of the renin angiotensin system inhibition. BMC Geriatr9, 48.
42.
BarnesJM, BarnesNM, CostallB, HorovitzZP, NaylorRJ (1989) Angiotensin II inhibits the release of [3H]acetylcholine from rat entorhinal cortex in vitro. Brain Res491, 136–143.
43.
MinersJS, RaikerM, LoveS, KehoePG (2010) ACE variants and association with brain Aβ levels in Alzheimer’s disease. Am J Transl Res3, 8.
44.
MinersS, AshbyE, BaigS, HarrisonR, TaylerH, SpeedyE, PrinceJA, LoveS, KehoePG (2009) Angiotensin-converting enzyme levels and activity in Alzheimer’s disease: Differences in brain and CSF ACE and association with ACE1 genotypes. Am J Transl Res1, 163–177.
45.
MogiM, LiJM, TsukudaK, IwanamiJ, MinLJ, SakataA, FujitaT, IwaiM, HoriuchiM (2008) Telmisartan prevented cognitive decline partly due to PPAR-gamma activation. Biochem Biophys Res Commun375, 446–449.
46.
WangJ, HoL, ChenL, ZhaoZ, ZhaoW, QianX, HumalaN, SerorI, BartholomewS, RosendorffC, PasinettiGM (2007) Valsartan lowers brain beta-amyloid protein levels and improves spatial learning in a mouse model of Alzheimer disease. J Clin Invest117, 3393–3402.
McKhannG, DrachmanD, FolsteinM, KatzmanR, PriceD, StadlanEM (1984) Clinical diagnosis of Alzheimer’s disease: Report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer’s Disease. Neurology34, 939–944.
49.
RosenWG, TerryRD, FuldPA, KatzmanR, PeckA (1980) Pathological verification of ischemic score in differentiation of dementias. Ann Neurol7, 486–488.
50.
FrisoniGB, FoxNC, JackCRJr., ScheltensP, ThompsonPM (2010) The clinical use of structural MRI in Alzheimer disease. Nat Rev Neurol6, 67–77.
51.
ChanD, JanssenJC, WhitwellJL, WattHC, JenkinsR, FrostC, RossorMN, FoxNC (2003) Change in rates of cerebral atrophy over time in early-onset Alzheimer’s disease: Longitudinal MRI study. Lancet362, 1121–1122.
FoxNC, RidgwayGR, SchottJM (2011) Algorithms, atrophy and Alzheimer’s disease: Cautionary tales for clinical trials. Neuroimage57, 15–18.
54.
FoxNC, ScahillRI, CrumWR, RossorMN (1999) Correlation between rates of brain atrophy and cognitive decline in AD. Neurology52, 1687–1689.
55.
HuaX, GutmanB, BoyleCP, RajagopalanP, LeowAD, YanovskyI, KumarAR, TogaAW, JackCRJr, SchuffN, AlexanderGE, ChenK, ReimanEM, WeinerMW, ThompsonPM, Alzheimer’s Disease Neuroimaging Initiative (2011) Accurate measurement of brain changes in longitudinal MRI scans using tensor-based morphometry. Neuroimage57, 10.
56.
FreeboroughPA, FoxNC (1997) The boundary shift integral: An accurate and robust measure of cerebral volume changes from registered repeat MRI. IEEE Trans Med Imaging16, 623–629.
57.
FreeboroughPA, FoxNC, KitneyRI (1997) Interactive algorithms for the segmentation and quantitation of 3-D MRI brain scans. Comput Methods Programs Biomed53, 15–25.
58.
LeungKK, BarnesJ, ModatM, RidgwayGR, BartlettJW, FoxNC, OurselinS (2011) Brain MAPS: An automated, accurate and robust brain extraction technique using a template library. Neuroimage55, 1091–1108.
59.
LeungKK, BarnesJ, RidgwayGR, BartlettJW, ClarksonMJ, MacdonaldK, SchuffN, FoxNC, OurselinS (2010) Automated cross-sectional and longitudinal hippocampal volume measurement in mild cognitive impairment and Alzheimer’s disease. Neuroimage51, 1345–1359.
60.
SallowayS, SperlingR, FoxNC, BlennowK, KlunkW, RaskindM, SabbaghM, HonigLS, PorsteinssonAP, FerrisS, ReichertM, KetterN, NejadnikB, GuenzlerV, MiloslavskyM, WangD, LuY, LullJ, TudorIC, LiuE, GrundmanM, YuenE, BlackR, BrashearHR, Bapineuzumab 301 and 302 Clinical Trial Investigators (2014) Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer’s disease. N Engl J Med370, 322–333.
61.
Jorge CardosoM, LeungK, ModatM, KeihaninejadS, CashD, BarnesJ, FoxNC, OurselinS, Alzheimer’s Disease Neuroimaging Initiative (2013) STEPS: Similarity and Truth Estimation for Propagated Segmentations and its application to hippocampal segmentation and brain parcelation. Med Image Anal17, 671–684.
62.
LeungKK, ClarksonMJ, BartlettJW, CleggS, JackCRJr, WeinerMW, FoxNC, OurselinS (2010) Robust atrophy rate measurement in Alzheimer’s disease using multi-site serial MRI: Tissue-specific intensity normalization and parameter selection. Neuroimage50, 516–523.
63.
MelbourneA, ToussaintN, OwenD, SimpsonI, AnthopoulosT, De VitaE, AtkinsonD, OurselinS (2016) NiftyFit: A software package for multi-parametric model-fitting of 4D magnetic resonance imaging data. Neuroinformatics14, 319–337.
64.
SudreCH, CardosoMJ, BouvyWH, BiesselsGJ, BarnesJ, OurselinS (2015) Bayesian model selection for pathological neuroimaging data applied to white matter lesion segmentation. IEEE Trans Med Imaging34, 2079–2102.
65.
RosenWG, MohsRC, DavisKL (1984) A new rating scale for Alzheimer’s disease. Am J Psychiatry141, 1356–1364.
66.
CummingsJL, MegaM, GrayK, Rosenberg-ThompsonS, CarusiDA, GornbeinJ (1994) The Neuropsychiatric Inventory: Comprehensive assessment of psychopathology in dementia. Neurology44, 2308–2314.
67.
BucksRS, AshworthDL, WilcockGK, SiegfriedK (1996) Assessment of activities of daily living in dementia: Development of the Bristol Activities of Daily Living Scale. Age Ageing25, 113–120.
68.
SmithSC, LampingDL, BanerjeeS, HarwoodR, FoleyB, SmithP, CookJC, MurrayJ, PrinceM, LevinE, MannA, KnappM (2005) Measurement of health-related quality of life for people with dementia: Development of a new instrument (DEMQOL) and an evaluation of current methodology. Health Technol Assess9, 1–93, iii-iv.
69.
ZekryD, DuyckaertsC, MouliasR, BelminJ, GeoffreC, HerrmannF, HauwJJ (2002) Degenerative and vascular lesions of the brain have synergistic effects in dementia of the elderly. Acta Neuropathol103, 481–487.
70.
JinJ, SklarGE, Min Sen OhV, Chuen LiS (2008) Factors affecting therapeutic compliance: A review from the patient’s perspective. Ther Clin Risk Manag4, 269–286.
71.
ScheltensP, LeysD, BarkhofF, HugloD, WeinsteinHC, VermerschP, KuiperM, SteinlingM, WoltersEC, ValkJ (1992) Atrophy of medial temporal lobes on MRI in “probable” Alzheimer’s disease and normal ageing: Diagnostic value and neuropsychological correlates. J Neurol Neurosurg Psychiatry55, 967–972.
72.
GoldbergAI, DunlayMC, SweetCS (1995) Safety and tolerability of losartan potassium, an angiotensin II receptor antagonist, compared with hydrochlorothiazide, atenolol, felodipine ER, and angiotensin-converting enzyme inhibitors for the treatment of systemic hypertension. Am J Cardiol75, 793–795.
73.
BraunV, ClarkeV (2006) Using thematic analysis in psychology. Qual Res Psychol3, 77–101.
74.
SandelowskiM (1995) Sample size in qualitative research. Res Nurs Health18, 179–183.
75.
ThompsonWK, HollandD (2011) Bias in tensor based morphometry Stat-ROI measures may result in unrealistic power estimates. Neuroimage57, 1–4; discussion 5-14.
